In the context of metabolic diseases, liposomal formulations have been explored for delivering insulin and insulin analogs [4,5], biguanide used in diabetes (e.g., metformin), lipid-lowering agents, including statins (e.g., atorvastatin, simvastatin [6,7] and fibrates (e.g., fenofibrate) [8], sulfonylureas (e.g., glibenclamide) [9], and anti-obesity drugs [10,11]. This evidence concerns the gene INS and Other metabolic disease.